Detection of prostate cancer and its recurrence is challenging as it is a heterogeneous disease and methods such as PET imaging and measurement of biochemical response using prostate specific membrane ...
Getty Images Ga 68 PSMA-11 PET can detect sites of local recurrence or metastasis in patients with biochemical evidence of recurrent prostate cancer. The FDA has approved gallium 68 PSMA-11 (Ga 68 ...
Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) ...
This Coordinated Research Project is the result of recommendations from the scientific community through interactions with IAEA technical officers. Prostate cancer is the most common solid malignancy ...
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show. Pelvic lymph node dissection still may be ...
For years, prostate cancer specialists hit a wall when prostate-specific antigen (PSA) levels crept up after definitive treatment. The cancer was likely back — but where? And to what extent? Bone plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results